Aldeyra Therapeutics (FRA:137) Cyclically Adjusted PB Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:137 Aldeyra Therapeutics Inc FRA:137
29 GF Score
Price €1.34
! 2 Warning Signs
View Full Analysis

What is Aldeyra Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Aldeyra Therapeutics  (FRA:137) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Aldeyra Therapeutics Cyclically Adjusted PB Ratio Related Terms


Aldeyra Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Aldeyra Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aldeyra Therapeutics Cyclically Adjusted PB Ratio Chart

Aldeyra Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 4.19 1.47 1.84 2.07

Aldeyra Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.45 2.03 2.07 0.68 0.00

FRA:137 vs NTHI, BMEA, PTHS: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Aldeyra Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aldeyra Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Aldeyra Therapeutics's Cyclically Adjusted PB Ratio falls into.


FRA:137
29GF Score
Aldeyra Therapeutics Inc FRA:137
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aldeyra Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Aldeyra Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Aldeyra Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.545/333.9520*333.9520
=0.545

Current CPI (Jun. 2026) = 333.9520.

Aldeyra Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 1.820 241.428 2.517
201612 1.632 241.432 2.257
201703 1.730 243.801 2.370
201706 1.371 244.955 1.869
201709 2.015 246.819 2.726
201712 1.749 246.524 2.369
201803 1.485 249.554 1.987
201806 1.519 251.989 2.013
201809 1.168 252.439 1.545
201812 2.901 251.233 3.856
201903 2.581 254.202 3.391
201906 2.208 256.143 2.879
201909 1.701 256.759 2.212
201912 1.510 256.974 1.962
202003 1.333 258.115 1.725
202006 1.421 257.797 1.841
202009 1.520 260.280 1.950
202012 1.265 260.474 1.622
202103 2.222 264.877 2.801
202106 3.344 271.696 4.110
202109 3.217 274.310 3.916
202112 3.135 278.802 3.755
202203 2.970 287.504 3.450
202206 2.824 296.311 3.183
202209 2.797 296.808 3.147
202212 2.434 296.797 2.739
202303 2.180 301.836 2.412
202306 2.039 305.109 2.232
202309 1.947 307.789 2.113
202312 1.856 306.746 2.021
202403 1.756 312.332 1.878
202406 1.537 314.175 1.634
202409 1.288 315.301 1.364
202412 1.137 315.605 1.203
202503 0.980 319.799 1.023
202506 0.798 322.561 0.826
202509 0.697 324.800 0.717
202512 0.628 324.054 0.647
202603 0.605 330.213 0.612
202606 0.545 333.952 0.545

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aldeyra Therapeutics Business Description

Other Exchanges ALDX:USA137:Germany
Address 131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
29GF Score

Get the complete analysis for FRA:137

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.34
Price